Botulinum Toxin—What Urologic Uses Does the Data Support?
Botulinum toxin-A (BTX-A) is well established in the management of various aspects of lower urinary tract dysfunction (LUTD). One formulation, OnabotulinumtoxinA has recently been licensed in many parts of the world for use in neurogenic detrusor overactivity (NDO), and in the US for idiopathic overactive bladder (OAB), in patient’s refractory to antimuscarinics. This review article looks at recent clinical publications that examine the use of BTX-A for the treatment of LUTD with a focus on OAB, detrusor overactivity (DO), benign prostatic hyperplasia (BPH) and Painful bladder syndrome / interstitial cystitis (PBS / IC). A literature review was conducted using the PubMed database and studies that were published within the time frame of January 2011 to present were included. Large randomised placebo controlled trials and a pooled analysis of patients with multiple sclerosis / spinal cord injury and NDO has suggested that BTX-A improved urinary incontinence (UI) episodes, urodynamic parameters and QoL in these patients. 200 U of OnabotulinumtoxinA appeared equivalent to 300 U. In patients with OAB, lower doses of 100 U OnabotulinumtoxinA, appear efficacious and with an acceptable adverse event profile. In one large phase III trial, de novo clean intermittent catheterisation rates were 6.1 %. Repeated injections in DO appear efficacious. Results from BPH studies are mixed, and the largest randomised study in this setting has shown significant improvements in a number of parameters for a variety of OnabotulinumtoxinA doses, but none of the doses were statistically better than placebo. Few studies have been conducted in PBS / IC and larger scale randomised placebo controlled trials are required to validate its use in this setting.
KeywordsDetrusor overactivity Overactive bladder Painful bladder syndrome Interstitial cystitis Benign prostatic hyperplasia Botulinum toxin A
Papers of particular interest, published recently, have been highlighted as: • Of importance
- 1.Abrams P, Andersson KE, Birder L, Brubaker L, Cardozo L, Chapple C, et al. Fourth International Consultation on Incontinence Recommendations of the International Scientific Committee: evaluation and treatment of urinary incontinence, pelvic organ prolapse, and fecal incontinence. Neurourol Urodyn. 2010;29(1):213–40.PubMedCrossRefGoogle Scholar
- 3.• Cruz F, Herschorn S, Aliotta P, Brin M, Thompson C, Lam W, et al. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur Urol. 2011;60(4):742–50. Large phase III RCT in NDO pts with MS and SCI showing good efficacy for 200 and 300 U OnabotulinumtoxinA..PubMedCrossRefGoogle Scholar
- 4.• Ginsberg D, Gousse A, Keppenne V, Sievert KD, Thompson C, Lam W, et al. Phase III efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity. J Urol. 2012;187(6):2131–9. Large phase III multi-centre RCT of NDO pts with MS and SCI showing good efficacy of 200 and 300 U OnabotulinumtoxinA..PubMedCrossRefGoogle Scholar
- 8.• Kennelly M, Dmochowski R, Ethans K, Karsenty G, Schulte-Baukloh H, Jenkins B, et al. Long-term efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence Due to neurogenic detrusor overactivity: an interim analysis. Urology. 2013;81(3):491–7. Efficacy of repeated injections of BTX-A in NDO patients..PubMedCrossRefGoogle Scholar
- 12.Sussman D, Patel V, Del Popolo G, Lam W, Globe D, Pommerville P. Treatment satisfaction and improvement in health-related quality of life with onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity. Neurourol Urodyn. 2013;32(3):242–9.Google Scholar
- 14.Jia C, Liao LM, Chen G, Sui Y. Detrusor botulinum toxin A injection significantly decreased urinary tract infection in patients with traumatic spinal cord injury. Spinal Cord. 2013. doi:10.1038/sc.2012.180.
- 15.• Nitti VW, Dmochowski R, Herschorn S, Sand P, Thompson C, Nardo C et al. OnabotulinumtoxinA for the Treatment of Patients with Overactive Bladder and Urinary Incontinence: Results of a Phase III Randomized Placebo-Controlled Trial. J Urol. 2012. doi:10.1016/j.juro.2012.12.022. Large phase III RCT assessing OnabotulinumtoxinA at 100 U verus placebo.
- 17.Fowler CJ, Auerbach S, Ginsberg D, Hale D, Radziszewski P, Rechberger T, et al. OnabotulinumtoxinA improves health-related quality of life in patients with urinary incontinence due to idiopathic overactive bladder: a 36-week, double-blind, placebo-controlled, randomized, dose-ranging trial. Eur Urol. 2012;62(1):148–57.PubMedCrossRefGoogle Scholar
- 18.Rovner E, Kennelly M, Schulte-Baukloh H, Zhou J, Haag-Molkenteller C, Dasgupta P. Urodynamic results and clinical outcomes with intradetrusor injections of onabotulinumtoxinA in a randomized, placebo-controlled dose-finding study in idiopathic overactive bladder. Neurourol Urodyn. 2011;30(4):556–62.PubMedCrossRefGoogle Scholar
- 25.Manecksha RP, Cullen IM, Ahmad S, McNeill G, Flynn R, McDermott TE, et al. Prospective randomised controlled trial comparing trigone-sparing versus trigone-including intradetrusor injection of abobotulinumtoxinA for refractory idiopathic detrusor overactivity. Eur Urol. 2012;61(5):928–35.PubMedCrossRefGoogle Scholar
- 26.Alloussi SH, Lang C, Eichel R, Al-Kaabneh A, Seibold J, Schwentner C, et al. Videourodynamic changes of botulinum toxin A in patients with neurogenic bladder dysfunction (NBD) and idiopathic detrusor overactivity (IDO) refractory to drug treatment. World J Urol. 2012;30(3):367–73.PubMedCrossRefGoogle Scholar
- 28.• Kuo H-C. Bladder base/trigone injection is safe and as effective as bladder body injection of OnabotulinumtoxinA for idiopathic detrusor overactivity refractory to antimuscarinics. Neurourol Urodyn. 2011;30(7):1242–8. Open label study assessing different BTX-A injection techniques in the bladder..PubMedGoogle Scholar
- 36.Sacco E, Bientinesi R, Marangi F, Totaro A, D'Addessi A, Racioppi M, et al. Patient-reported outcomes in men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) treated with intraprostatic OnabotulinumtoxinA: 3-month results of a prospective single-armed cohort study. BJU Int. 2012;110(11 Pt C):E837–44.PubMedCrossRefGoogle Scholar
- 38.• Marberger M, Chartier-Kastler E, Egerdie B, Lee KS, Grosse J, Bugarin D, et al. A randomized double-blind placebo-controlled phase II dose-ranging study of onabotulinumtoxinA in men with benign prostatic hyperplasia. Eur Urol. 2013;63(3):496–503. Largest RCT assessing BTX-A injections vs placebo into the prostate for BPH..PubMedCrossRefGoogle Scholar
- 43.Chung SD, Kuo YC, Kuo HC. Intravesical onabotulinumtoxinA injections for refractory painful bladder syndrome. Pain Phys. 2012;15(3):197–202.Google Scholar